Cell death & diseaseDec 23, 2025

Loss of ELF2 may cause resistance to topotecan in retinoblastoma cancer

CRISPR Gene Editing Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jun 27, 2026

Abstract

Essence

Loss of ELF2 appears to make retinoblastoma cells less sensitive to topotecan by reducing apoptosis and shifting ATP-synthesis-related signaling.

Evidence

This translational preclinical study used genome-wide CRISPR-Cas9 screening, retinoblastoma cell assays, a mouse xenograft model, RNA sequencing, and a patient tumor-volume correlation after topotecan.

Caveat

The patient component is correlative and the resistance mechanism is mainly shown in cells and xenografts, so ELF2 is not yet a validated therapeutic target.

Simplified

The topoisomerase I inhibitor topotecan is an effective chemotherapeutic agent for retinoblastoma; however, treatment resistance remains a major clinical challenge, and its mechanisms remain elusive. Using genome-wide CRISPR-Cas9 knockout screening, we identified ELF2 as a key gene involved in topotecan resistance. Here, we show that surviving retinoblastoma cells exposed to topotecan showed progressively decreased ELF2 expression, accompanied by reduced apoptosis. In a mouse xenograft model, ELF2 disruption diminished the antitumor efficacy of topotecan, with ELF2-knockout cells exhibiting reduced topotecan-induced apoptosis. RNA sequencing further revealed that the MT-CYB pathway, associated with ATP synthesis, contributes to ELF2-mediated resistance. Importantly, clinical analysis demonstrated a correlation between ELF2 expression and tumor volume in retinoblastoma patients treated with topotecan. Together, these findings interrogate the mechanisms underlying topotecan resistance in retinoblastoma and suggest ELF2 as a potential therapeutic target to overcome drug resistance.

Full Text

Full text is available at the source.

View Full Text ↗

Featured in

CRISPR Gene EditingIssue #17

Rice base editors cut off-target edits 79.4x — while CRISPR activation can be controlled by light

↗

Loss of ELF2 may cause resistance to topotecan in retinoblastoma cancer

Abstract

Full Text

Featured in

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the crispr gene editing brief